| 李小波,杨龙娜,周国坚.三种中成药在左氧氟沙星基础上辅助治疗社区获得性肺炎(非重症,成人)的成本效果分析[J].中国药事,2018,32(8):1155-1160 |
| 三种中成药在左氧氟沙星基础上辅助治疗社区获得性肺炎(非重症,成人)的成本效果分析 |
| Cost-effectiveness Analysis of Three Chinese Patent Medicines in the Assisted Treatment of Community-acquired Pneumonia on the Basis of Levofloxacin |
| 投稿时间：2017-10-16 |
| DOI：10.16153/j.1002-7777.2018.08.025 |
| 中文关键词: 社区获得性肺炎 药物经济学 中成药 成本-效果分析 |
| 英文关键词: community-acquired pneumonia(CAP) pharmacoeconomics Chinese patent medicine costeffectiveness analysis |
| 基金项目:珠海市科技和工业信息化局珠海市科技计划医疗卫生项目，基于多中心临床EMR数据的单病种控费研究（编号20171009E030038） |
|
| 摘要点击次数: 1261 |
| 全文下载次数: 787 |
| 中文摘要: |
| 目的：分析四种临床治疗方案在治疗社区获得性肺炎的疗效和成本-效果分析，为临床中成药的合理用药提供参考。方法：采用回顾性研究法，通过查阅课题组采集的电子病历收集资料，并遴选出符合本研究和分组条件的病历共120例，分四组，每组30例，运用药物经济学的成本-效果分析，对其进行药物经济学分析评价。结果：喜炎平+左氧氟沙星组（A组）、热毒宁+左氧氟沙星组（B组）、痰热清+左氧氟沙星（C组）和单用左氧氟沙星（D组）四组的疗效评分治疗前相近，P>0.05，治疗后分别为2.362±1.755、2.475±1.715、2.336±1.523、4.102±2.563，中成药A组、B组、C组对比D组的治疗后疗效评分，P<0.05，差异显著，具有统计学意义；四组治疗效果相近，治愈率（E，%）分别为73.33、76.67、80.00、66.67；药品平均成本（C1，元）分别为1110、874、777、502，平均治疗总成本（C2，元）分别为6712、6236、6002、5837；成本效果比，C1/E分别为15.14、11.40、9.71、7.53，C2/E分别为91.53、81.34、75.03、87.55；敏感度分析A、B、C组参照D组的增量成本-效果比，△C1/△E分别为82.16、33.48、18.57，△C2/△E分别为118.24、35.91、11.14，药品平均成本和平均治疗总成本的敏感度分析结果具有一致性，且支持成本-效果分析结果。结论：热毒宁组（B组）和痰热清组（C组）"性价比"占优，其中痰热清组（C组）为最佳，在合理抗菌药物治疗基础上可作为治疗社区获得性肺炎优选的辅助中成药注射剂。 |
| 英文摘要: |
| Objective:To analyze efficacy and cost-effectiveness of four groups of clinical treatment of community-acquired pneumonia and to provide references for clinical rational use of Chinese patent medicines. Methods:The retrospective analysis method was used and electronic medical records collected by the research group were searched to collect data. A total of 120 cases in accordance with the study and grouping conditions were selected and divided into four groups with, 30 cases for each group. The cost-effectiveness analysis was carried out to evaluate their pharmacoeconomics. Results:The efficacy scores of the four groups were similar before treatment (P>0.05). The efficacy scores of Xiyanping plus levofloxacin group (group A), Reduning plus levofloxacin group (group B), Tanreqing plus levofloxacin group (group C) and levofloxacin group (group D) were 2.362±1.755,2.475±1.715,2.336±1.523,4.102±2.563 respectively after treatment. Compared with group D, the curative effect scores of groups A, B and C of Chinese patent medicine were different and statistically significant (P<0.05). The treatment effects of the four groups were similar, the cure rates(E,%)were 73.33, 76.67, 80.00 and 66.67 respectively. The average cost of drugs (C1, yuan) were 1110, 874, 777 and 502, the average total cost of treatment (C2, yuan) were 6712, 6236, 6002 and 5837. As far as the cost-effectiveness ratios were concerned, C1/E were 15.14, 11.40, 9.71, 7.53 and C2/E were 91.53, 81.34, 75.03, 87.55. The incremental cost-effectiveness ratios of groups A, B and C compared to group D, △C1/△E were 82.16, 33.48, 18.57 and△C2/△E were 118.24, 35.91, 11.14.The results of sensitivity analysis for the average drug cost and average total cost of treatment were consistent and supported the results of cost-effectiveness analysis. Conclusion:Reduning group (group B) and Tanreqing group (group C) had higher cost performance ratios, of which Tanreqing group (group C) was better and can be used as a preferred auxiliary Chinese patent medicine injection for the treatment of community-acquired pneumonia based on rational antibacterial treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|